Covid-19 roundup: In­otrem loads up on French fund­ing to take sep­tic shock can­di­date to the next stage; Bel­gian woman dies af­ter be­ing in­fect­ed with 2 vari­ants of con­cern

When Roche vet Jean-Jacques Ga­raud helped found French start­up In­otrem, he was at­tract­ed by the com­pa­ny’s im­munother­a­py for sep­tic shock. Now, that can­di­date is mov­ing in­to late-stage test­ing in se­vere Covid-19 pa­tients — and In­otrem is get­ting about $53 mil­lion (€45 mil­lion) more from France to ad­vance the tri­al.

Nan­gi­botide is en­ter­ing a Phase II/III study in up to 730 Covid-19 pa­tients in France and Bel­gium who are on ven­ti­la­tors, the com­pa­ny said on Mon­day. Re­searchers will look to see if the can­di­date im­pacts pro­gres­sion of dis­ease, sever­i­ty of res­pi­ra­to­ry fail­ure, du­ra­tion of me­chan­i­cal ven­ti­la­tion, length of stay in the ICU and deaths.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER